ClinicalTrials.gg
RecruitingNCT05440851PRACTICALUpdated Oct 22, 2026

Platform of Randomized Adaptive Clinical Trials in Critical Illness

An interventional study of Ultra-Protective Ventilation Facilitated by Extracorporeal Support and Lung-Protective Ventilation (LPV) in Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication and Mechanical Ventilation Pressure High, sponsored by University Health Network, Toronto. Recruiting at 103 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.
Updated Oct 22, 2026First site in Hong KongSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Respiratory Insufficiency by University Health Network, Toronto — 7 open to participants now, 8 under way, none of them phase 3. Respiratory Insufficiency · University Health Network, Toronto.

Started
2023
with 2 others
No phase
7 of 14
4 open now
Registered
9th of 14
by date

Among the 14 studies in Respiratory Insufficiency by University Health Network, Toronto, this one is one of 3 that started in 2023, is one of 7 with no phase, and was the 9th registered.

Respiratory Insufficiency

1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.

Browse Respiratory Insufficiency studies →

Open to participants now

7 of the 14 studies in Respiratory Insufficiency by University Health Network, Toronto are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Respiratory Insufficiency by University Health Network, Toronto, or all of them as a file.
02

Study summary

PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states (i.e., not intubated, intubated with lower or higher respiratory system elastance, requiring extracorporeal life support) and across a range of investigational phases (i.e., preliminary mechanistic trials, full-scale clinical trials). AHRF is a common and life-threatening clinical syndrome affecting millions globally every year. Patients with AHRF are at high risk of death and long-term morbidity. Patients who require invasive mechanical ventilation are at risk of ventilator-induced lung injury and ventilator-induced diaphragm dysfunction. New treatments and treatment strategies are needed to improve outcomes for these very ill patients.

Utilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices.

The platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes.

A domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. A domain may also be a non-interventional study that addresses observational research questions by collecting specific data or outcomes that are not collected as part of other domains. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies and mechanistic pathways within the same patient.

Once feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial.

In general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\<2.5 cm H2O/(mL/kg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O/(mL/kg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time.

Where possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.

Read the detailed description

EXPAND-ECLS domain: The EXPAND-ECLS pilot trial is a multi-center, randomized, open-label, feasibility trial, embedded as a domain within the PRACTICAL platform trial. The ULTIMATE arm of this domain will evaluate the effect of ultra-low intensity ventilation facilitated by CO2 removal through VV-ECMO versus best current conventional ventilation on all-cause hospital mortality among patients with early moderate-severe AHRF with high respiratory system elastance receiving potentially injurious mechanical ventilation. The PROACTIVE arm of this domain will evaluate the effect of ECMO-facilitated strategy of earlier awakening, extubation, and rehabilitation versus best current conventional ventilation on all-cause hospital mortality among patients with early moderate-severe AHRF with high respiratory system elastance receiving potentially injurious mechanical ventilation.

Invasive Mechanical Ventilation (IMV) Strategies domain: The IMV Strategies domain will evaluate multiple novel invasive ventilation strategies in comparison to conventional lung-protective ventilation in patients with acute hypoxemic respiratory failure (AHRF). Multiple approaches to mechanical ventilation are used, and the optimal approach is unknown. An efficient strategy to identify the best strategy is to compare multiple potential approaches simultaneously to determine more rapidly (a) which interventions are least effective (and should be dropped), and (b) which interventions result in the best outcomes for patients. In the current domain design, we will compare the current recommended ventilation strategy to two new approaches: a strategy that targets lung-inflating (driving) pressure instead of lung-inflating (tidal) volume, and a strategy that aims to maintain an optimal level of breathing effort to prevent diaphragm atrophy and injury while maintaining safe lung-inflating pressures.

CORT-E2 domain: The Corticosteroid Early and Extended (CORT-E2) Trial is a phase III, multicentre Bayesian randomized controlled trial (RCT), which includes two cohorts within the domain; one examining the role of early corticosteroids as compared to not extending in persisting AHRF due to COVID or non-COVID (Extended Cohort).

ESCAPE domain: Evaluating Subphenotypes in Immunocompromized Patients with ARF (ESCAPE) Domain is a prospective, multicentre observational cohort study, to identify subphenotypes across immunocompromised patients with acute hypoxemic respiratory failure (AHRF) using clinical characteristics and biomarkers. This study will prospectively collect biomarkers at the onset of AHRF which will allow us to characterize the underlying pathophysiology of AHRF with better precision.

WAVEFORM domain: The Clinical Implications of Potentially Injurious Patient-Ventilator Interactions (WAVEFORM domain) a prospective, multicentre observational cohort study, that aims at understanding the short- and long-term clinical consequences of longitudinal exposure to abnormal patient ventilation interactions in patients with AHRF, role of sedation as a mediator in this relationship. It aims at also exploring the heterogeneity of treatment effect of various mechanical ventilation strategies tested in the IMV based on the presence and burden of abnormal patient-ventilator interactions.

FLUDRO domain: The Fludrocortisone in Acute Hypoxemic Respiratory Failure with Airspace Disease (FLUDRO-1) domain is a phase II I trial. The trial aims to provide direct clinical evidence to resolve a critical long-standing question regarding the use of steroids in the treatment of AHRF with airspace disease.

FAST-3 domain: The Nebulized Furosemide for the Treatment of Pulmonary Inflammation in Patients with Respiratory Failure Secondary to Pulmonary Infection domain is a phase III trial. It aims to use nebulized furosemide as supportive therapy to improve Advanced Respiratory Support (ARS) free days up to day 28 in critically ill patients with AHRF.

IMV-ECLS domain: The Invasive Mechanical Ventilation Strategies in Venovenous-Extracorporeal Life Support (PRESSURE; Positive Pressure to Maintain Lung Recruitment during Extracorporeal Life Support for Acute Hypoxemic Respiratory failure) is a pilot and feasibility trial. It aims to identify which positive end-expiratory pressure (PEEP) strategies improve lung function in patients with AHRF supported by ECLS.

IMPROV domain: The Inspiratory Muscle Training in Patients Receiving Ongoing Mechanical Ventilation is a pilot and feasibility RCT. It is designed to establish the feasibility of a definitive RCT of inspiratory muscle training to accelerate recovery from AHRF.

03

Conditions studied

  • Respiratory Insufficiency
  • Extracorporeal Membrane Oxygenation Complication
  • Mechanical Ventilation Pressure High
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

PRACTICAL Platform Inclusion Criteria:

  1. Acute hypoxemic respiratory failure meeting all of the following criteria;

    1. New or worsening respiratory symptoms developing within 2 weeks prior to the onset of need for oxygen or respiratory support
    2. Receiving any of the following types of oxygen or respiratory support for at least 4 hours prior to the time of randomization; supplemental oxygen at 10 L/min or higher, high flow nasal oxygen (at any flow rate), invasive ventilator support, extra-corporeal life support (ECLS), or non-invasive ventilator support
    3. Minimum FiO2 ≥ 0.40 (for venturi mask, high flow nasal cannula, or invasive or non-invasive ventilation) or oxygen flow rate ≥10 L/min on face mask for at least 4 hours at the time of evaluation for eligibility unless already on extra-corporeal life support
  2. Age ≥ 18 years
  3. Hypoxemia not primarily attributable to acute heart failure, fluid overload, or pulmonary embolism (PE)

PRACTICAL Platform Exclusion Criteria:

  1. Extubation is planned or anticipated on the day of screening
  2. ICU discharged is planned or anticipated on the day of screening
  3. If the patient is moribund and deemed unlikely to survive 24 hours (as determined by the clinical team)
  4. If the patient is being transitioned to a fully palliative philosophy of care

EXPAND-ECLS Domain Inclusion Criteria:

  1. Receiving invasive Endotracheal mechanical ventilation for ≤ 72 hours.5 days
  2. Early Moderate-severe hypoxemic respiratory failure with a PaO2/FiO2≤150200 mmHg for at least 6 hours

EXPAND-ECLS Domain Exclusion Criteria:

  1. Patients over 70 years of age.
  2. Currently receiving any form of ECLS (e.g., Venovenous, venoarterial, or hybrid configuration).
  3. Chronic hypercapnic respiratory failure defined as PaCO2 > 60 mmHg in the outpatient setting.
  4. Home mechanical ventilation (non-invasive ventilation or via tracheotomy) except for CPAP/BiPAP used solely for sleep-disordered breathing.
  5. Actual body weight exceeding 1 kg per centimeter of height.
  6. More than 48 hours have passed since meeting inclusion criteria.
  7. Severe hypoxemia with PaO2/FiO2 \< 80mmHg for > 6 hours at time of screening.
  8. Severe hypercapnic respiratory failure with pH \< 7.25 and PaCO2 > 60 mmHg for > 6 hours at time of screening.
  9. Expected mechanical ventilation duration \< 48 hours at time of screening.
  10. Confirmed diffuse alveolar hemorrhage from vasculitis.
  11. to limited anticoagulation (e.g., active GI bleeding, bleeding diathesis).
  12. Previous /anaphylactic reaction to heparin or heparin-induced thrombocytopenia
  13. Neurologic conditions at risk for or undergoing treatment for intracranial hypertension
  14. Underlying illness with \< 1 year
  15. Pregnancy (due to unknown effects of PaCO2 changes on placental blood flow)
  16. Respiratory failure known or suspected to be caused by COVID-19.

IMV Domain Inclusion Criteria:

  1. Intubated patients, not on ECLS, with low normalized respiratory elastance (\<2.5 cm H2O/(ml/kg predicted body weight)) at the time of eligibility assessment OR
  2. Intubated patients, not on ECLS, with high normalized respiratory system elastance (≥2.5 cm H2O/(ml/kg predicted body weight)) at the time of eligibility assessment OR
  3. FOR STUDY SITES PARTICIPATING IN THE LDPVS INTERVENTION: Patient is on ECLS at the time of eligibility assessment. Note: Patients in this state are only eligible for the LPV or LDPVS intervention
  4. FOR STUDY SITES PARTICPATING IN THE EIT INTERVENTION: PaO2/FiO2 (if available) \< 200 mm Hg at randomization. If PaO2/FiO2 has not been measured, SpO2 = 97% on FiO2 =60%.

IMV Domain Exclusion Criteria:

  1. PaO2/FiO2 >300 mm Hg or (S/F >250, if PaO2/FiO2 has not been measured) at the time of randomization
  2. Chronic hypercapnic respiratory failure defined as PaCO2>60mmHg in the outpatient setting
  3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated
  4. Severe hypoxemia with PaO2/FiO2\<80mmHg for >6 consecutive hours at the time of randomization
  5. Severe hypercapnic respiratory failure with pH\<7.25 and PaCO2>60mmHg for >6 consecutive hours at the time of randomization
  6. Anticipated duration of mechanical ventilation is \<48 hours from the time of screening
  7. Duration of mechanical ventilation during current ICU admission is >72 hours
  8. Previously diagnosed neuromuscular disorder
  9. Current diagnosis of severe acute brain injury (e.g. ischemic or hemorrhagic stroke, traumatic brain injury) with Glasgow Coma Scale ≤ 8
  10. Baseline weight prior to or at hospital admission less than 35 kilograms
  11. Receiving extracorporeal life support without continuous invasive mechanical ventilatory support

CORT-E2 Domain Early Cohort Inclusion Criteria

  1. Within 72 hours of admission to an ICU
  2. New unilateral or bilateral airspace disease

CORT-E2 Domain Early Domain Exclusion Criteria

  1. Receiving only low flow oxygen therapy less than or equal to 15L/min
  2. use during the 14 days prior to screening
  3. Existing indication for corticosteroids
  4. High suspicion for/or confirmed COVID infection
  5. Acute traumatic brain injury during the index hospital admission
  6. Allergy to dexamethasone

CORT-E2 Domain Extended Cohort Inclusion Criteria

  1. Are admitted to an ICU
  2. Have already received 10 days of corticosteroid specifically for acute respiratory failure, this will include patients: (a) randomized to corticosteroid arm in Early Cohort, (b) patients with COVID receiving corticosteroids as standard of care , (c) and others who have received corticosteroids for AHRF
  3. Ongoing AHRF requiring HFNC, NIV (continuous positive airway pressure [CPAP] or bilevel) or invasive ventilation

CORT-E2 Domain Extended Cohort Exclusion Criteria

  1. An alternate indication for ongoing corticosteroids
  2. Acute traumatic brain injury this hospital admission

FLUDRO Domain Inclusion Criteria 1. Within 72 hours of admission to an ICU

FLUDRO Domain Exclusion Criteria

  1. Known hypersensitivity to fludrocortisone
  2. An inability to receive fludrocortisone due to lack of enteral access
  3. An indication to prescribe fludrocortisone for a reason that is unrelated to a current episode of pneumonia or acute respiratory failure, such as Addison's disease
  4. Belief of the treating clinical team that study participation would not be in the best interest of the patient

FAST-3 Domain Inclusion Criteria (must meet all 3 of the following)

  1. Patient is in a PRACTICAL eligible platform state and requires advanced respiratory support (ARS) defined as one of the following:

    a. Invasive mechanical ventilation with FiO2 > 40% b. Non-Invasive Ventilation (> 4 hours consecutively with FiO2 > 40%) defined as: i. CPAP or BiPAP (any settings or interface) ii. HFNC (flow > 40 liter per minute)

  2. PaO2/FiO2 \< 300 mm Hg or SpO2/FiO2 \< 315 (if PaO2/FiO2 unavailable due to lack of arterial blood gas at the time of screening). For SpO2/FiO2, criteria are SpO2 ≤ 97% on FiO2 ≥ 40% on both of the 2 hours immediately preceding eligibility assessment. If an arterial blood gas can be obtained, then a PaO2/FiO2 ratio is preferable.
  3. Patient commenced advanced respiratory support \< 48 hours prior to randomization.

FAST-3 Domain Exclusion Criteria

  1. Patient commenced advanced respiratory support > 48 hours to time of randomization.
  2. Known history of severe chronic pulmonary disease e.g., pre-infection requirement for home oxygen therapy or presence of chronic hypercapnia (PaCO2 > 60 mmHg); mild - moderate disease is still eligible in the absence of chronic hypercapnia or need for chronic oxygen therapy.
  3. Currently enrolled in another trial studying anti-inflammatory therapy, excluding established treatments used in clinical practice such as corticosteroids.
  4. Known allergy to furosemide or sulfonamide drugs. If the patient is allergic to sulfonamide drugs but has received in the past or is currently receiving furosemide without incident, they can be enrolled since cross-reactivity between furosemide and sulfonamide agents is rare.

ESCAPE Domain Inclusion Criteria

  1. Patients with severe AHRF who have an underlying condition
  2. Within 48 hours of fulfilling the AHRF inclusion criteria as well as PaO2/FiO2 \<300 or a SaO2/FiO2 \< 315 on non-invasive respiratory support (venturi mask, non-invasive ventilation or high flow nasal oxygen as per the FiO2 requirements above) or invasive ventilation.

Patients may be enrolled from the wards or ICU.

Immunocompromised patients include:

  1. Any patients requiring long term (>30 days) corticosteroids (>20 mg/day),
  2. Any patients receiving non-corticosteroid immunosuppressive medications within the prior 3 months,
  3. Acquired or inherited immunodeficiency syndrome,
  4. Recipients of solid organ transplant,
  5. Active hematologic (diagnosis or receiving treatment within prior 6 months),
  6. Active solid tumor (diagnosis or receiving treatment within the prior 6 months) or
  7. Any patients who have undergone or autologous hematopoietic cell transplant in the prior 6 months (HCT).

    ESCAPE Domain Exclusion Criteria

    1. Patients whom are deemed palliative.

    WAVEFORM Domain Inclusion Criteria

    1. Patient is intubated at the time of eligibility assessment.

    WAVEFORM Domain Exclusion Criteria

    1. PaO2/FiO2 >300 mm Hg or (S/F >250, if PaO2/FiO2 has not been measured) at the time of eligibility assessment.
    2. Duration of mechanical ventilation during current ICU admission is ≥72 hours.
    3. Receiving ECLS without continuous invasive mechanical ventilatory support.

    IMV-ECLS Domain Inclusion Criteria

    1. Patients with AHRF (as defined in platform inclusion criteria #1 above) who have been consented for cannulation for VV-ECLS or who have been initiated on VV-ECLS within 6 hours at the time of randomization

    IMV-ECLS Domain Exclusion Criteria 1. Patients receiving ECLS for the primary intention of extracorporeal CO2 removal 2. Patients expected to be liberated from ECLS within \<24 hours 3. History of recent pneumothorax or pneumomediastinum (\<3 months at the time of eligibility assessment/randomization) 4. Patients receiving ECLS for the primary intention of bridge to lung transplantation (at the time of eligibility assessment/randomization)

    IMPROV Domain Inclusion Criteria

    1. Patients receiving invasive mechanical ventilation for AHRF as defined by the PRACTICAL platform trial criteria above.
    2. Within 7 calendar days of intubation

    IMPROV Domain Exclusion Criteria

    1. Patient is expected to be liberated from mechanical ventilation within 24 hours
    2. Known or suspected chronic hypercapnic respiratory failure defined as PaCO2>60mmHg in the outpatient setting
    3. Home mechanical ventilation (non-invasive ventilation or via tracheotomy), not including nocturnal CPAP applied by nasal or face mask or home tracheotomy if not ventilated
    4. Known pneumothorax or pneumomediastinum without chest tube placement sustained during current ICU admission* (re-confirm immediately prior to randomization)
    5. Patient is admitted primarily for acute brain injury (stroke, traumatic brain injury, etc.)
    6. Previously diagnosed chronic neuromuscular disorder
    7. Patient has an implantable cardiac defibrillator or pacemaker
    8. Planned to be transferred to another hospital before ICU discharge
    9. Already receiving a regimen of inspiratory muscle training using external resistive device or diaphragm neurostimulation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
6,250 participants (estimated)

Study arms

  • Other
    Ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal.

    Patients randomized to the this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.

    Other: Ultra-Protective Ventilation Facilitated by Extracorporeal Support · Other: Lung-Protective Ventilation (LPV) · Other: VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation

  • Other
    Invasive Mechanical Ventilation (IMV) Strategies domain

    Patients on invasive mechanical ventilation in the low elastance, high elastance, and ECLS states will be randomized to minimum of one of two mechanical ventilation interventions (including conventional lung-protective ventilation as a control group). Most sites will randomize patients to two arms (one of which is the control group, LPV). A subset of sites will randomize patients to all three or four arms.

    Other: Lung-Protective Ventilation (LPV) · Other: Driving Pressure-Limited Ventilation (DPL) · Other: Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS) · Other: Electrical impedance tomography (EIT)

  • Other
    The Corticosteroid Early and Extended (CORT-E2) Randomized Controlled Trial domain

    Patients with acute hypoxemic respiratory failure (AHRF) requiring invasive or non-invasive respiratory support will be randomized in the Early Cohort to receive corticosteroid or usual care without corticosteroids. Patients treated with corticosteroids who still require invasive or non-invasive respiratory support after 10 days will be randomized in the Extended Cohort to extending corticosteroid use or stopping corticosteroids after 10 days.

    Drug: Early Cohort corticosteroid dose · Drug: Extended Cohort corticosteroid dose · Drug: Usual care without routine corticosteroids · Drug: Usual care without extending corticosteroids

  • Other
    The Nebulized Furosemide for the Treatment of Pulmonary Inflammation (FAST-3) domain

    Patients with Respiratory Failure Secondary to Pulmonary Infection.

    Drug: Drug 4 mL: · Drug: Drug 40 mg:

  • Other
    The Invasive Mechanical Ventilation Strategies in Venovenous-Extracorporeal Life Support (IMV-ECLS)

    Patients with acute hypoxemic respiratory failure receiving extracorporeal life support will be randomized to one of three positive end-expiratory pressure (PEEP) strategies.

    Other: PEEP-20 · Other: PEEP-AOP · Other: PEEP-10

  • Other
    The Fludrocortisone in Acute Hypoxemic Respiratory Failure with Airspace Disease (FLUDRO-1) domain

    Patients with acute hypoxemic respiratory failure with airspace disease will be randomized to usual care with or without fludrocortisone.

    Drug: Usual care with fludrocortisone · Drug: Usual care without fludrocortisone

  • Other
    VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation

    Patients with acute hypoxemic respiratory failure in the high elastance state will be randomized to ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal or to VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation or to conventional lung-protective ventilation.

    Other: Ultra-Protective Ventilation Facilitated by Extracorporeal Support · Other: Lung-Protective Ventilation (LPV) · Other: VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation

  • Other
    Evaluating Subphenotypes in Immunocompromized Patients with ARF (ESCAPE) Domain

    We will conduct a prospective, multicenter, observational study (no treatment arm is involved) in 7 ICUs in Canada over 3 years. We will include adult patients (≥18 years) admitted to the ICU with AHRF who have an underlying immunocompromised condition. Biomarker Collection: Samples for serum biomarkers will be collected within 24 hours of fulfilling inclusion criteria, on days 0, 3 and 7. We will collect biomarkers associated with inflammatory conditions, epithelial injury, endothelial dysfunction and coagulation abnormalities - which have been shown to characterize lung injury or critical illness. Data Collection: We will collect demographic, comorbidity, immunocompromised defining condition, clinical, respiratory physiology, and serum biomarker data for each patient.

    Other: no treatment / intervention arm is involved

  • Other
    Inspiratory Muscle Training in Patients Receiving Ongoing Mechanical Ventilation (IMPROV) Domain

    This domain studies inspiratory muscle training (IMT) during and after mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF).

    Other: Usual care · Other: Early Routine IMT

  • Other
    Clinical Implications of Potentially Injurious Patient-Ventilator Interactions (WAVEFORM) Domain

    This domain primarily aims at understanding the short-and long-term clinical consequences of longitudinal exposure to abnormal patient ventilator interactions.

    Other: no treatment / intervention arm is involved.

Interventions

  • OtherUltra-Protective Ventilation Facilitated by Extracorporeal Support

    Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.

  • OtherLung-Protective Ventilation (LPV)

    Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.

  • OtherDriving Pressure-Limited Ventilation (DPL)

    Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.

  • OtherLung- and Diaphragm-Protective Ventilation and Sedation (LDPVS)

    Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.

  • DrugEarly Cohort corticosteroid dose

    Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.

  • DrugExtended Cohort corticosteroid dose

    Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).

  • DrugUsual care without routine corticosteroids

    Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.

  • DrugUsual care without extending corticosteroids

    Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.

  • DrugUsual care with fludrocortisone

    Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.

  • DrugUsual care without fludrocortisone

    Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.

  • DrugDrug 4 mL:

    4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.

  • DrugDrug 40 mg:

    40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours

  • OtherPEEP-20

    fixed high positive end-expiratory pressure at 20 cmH2O

  • OtherPEEP-AOP

    positive end-expiratory pressure set according to airway opening pressure

  • OtherPEEP-10

    fixed lower positive end-expiratory pressure at 10 cmH2O

  • OtherVV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation

    Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.

  • OtherElectrical impedance tomography (EIT)

    Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.

  • Otherno treatment / intervention arm is involved

    This trial is a prospective, multicenter, observational study (no treatment arm is involved).

  • OtherUsual care

    Patients will be treated according to usual care.

  • OtherEarly Routine IMT

    * Training commences once patients meet readiness to wean criteria * 3 sets of 10 breaths, delivered twice daily using a device placed at the airway opening to apply an external resistive pressure load, until hospital discharge, death, or day 45 after randomization, whichever occurs first. * Device load will initially be set to 30% of the MIP. * Device load will be titrated upward (in increments of 5-10% of MIP, to a maximum of 60% of MIP) as needed to achieve a modified Borg dyspnea score of 7/10 or visible accessory muscle use.

  • Otherno treatment / intervention arm is involved.

    This trial is a prospective, multicenter, observational study (no treatment arm is involved).

06

What researchers measure

Primary outcomes

  1. EXPAND-ECLS domain - determine the feasibility of recruiting 100 patients over 2 years of active enrolment, as well as assess the rate of participant recruitment and understand the barriers to enrollment.

    Record total number of patients randomized, total number of patients eligible yet not randomized, and the number of active randomizing sites on a monthly basis. This will include evaluating the validity and appropriateness of inclusion and exclusion criteria, trial acceptability, and reasons for lack of consent or withdrawal.

    Time frame: 2 years of active site enrollment.

  2. FLUDRO-1 and IMV domains - ventilator-free days to day 28 in DPL vs LPV (DRIVE RCT)

    Ventilator-free days to day 28 is computed as an ordinal scale ranging between -1 to 28. Patients who die in hospital will be assigned a value of -1. Otherwise the endpoint will be computed from the number of days alive and free of ventilation in the period between the day the patient is liberated from mechanical ventilation and day 28.

    Time frame: Day 28 post randomization

  3. IMV domain - adherence to LDPVS management (LANDMARK RCT)

    Adherence to LDPVS management will be measured in terms of the proportion of protocol-specified measurements of respiratory effort that are on target during the intervention period.

    Time frame: Day 28

  4. IMV domain - probability of achieving and maintaining lung- and diaphragm-protective targets during mechanical ventilation (LANDMARK RCT)

    Lung- and diaphragm-protective targets are defined as an estimated dynamic trans pulmonary driving pressure ≤23 cm H2O and a Pocc value between -6 to -20 cm H2O.

    Time frame: Day 28

  5. IMV domain - protocol adherence (EIT intervention)

    Protocol adherence will be measured as a binary outcome daily, while patients are receiving EIT. The target protocol adherence across patients is ≥80%.

    Time frame: Day 9

  6. CORT-E2 domain - 60-day mortality from the day of randomization

    Time frame: Day 60

  7. FLUDRO-1 domain - Successful enrollment of participants

    Protocol adherence: e.g., proportion of participants randomized to fludrocortisone who received the study drug as specified in the protocol; Consent rate; Early withdrawal from domain intervention; Outcome completeness

    Time frame: 18-month enrolment period across three platform trials (PRACTICAL, REMAP-CAP and ATTACC-CAP)

  8. FAST-3 domain - Advanced respiratory support free days

    Advanced respiratory support free days (ARSFDs) to day 28, a composite outcome including mortality and requirement for respiratory support

    Time frame: Day 28

  9. IMV-ECLS domain - feasibility of enrollment and protocol adherence

    Feasibility of enrollment defined as ≥1 patient enrolled per month per site. Protocol adherence defined as ≥90% of patients initiated on assigned PEEP strategy within 6 hours of ECLS cannulation and ≥90% average protocol adherence across participants.

    Time frame: For feasibility of enrollment: 2 years of active site enrollment; For protocol adherence, these will be evaluated at 7 days (once the intervention period ends)

  10. ESCAPE domain - 28-day all-cause mortality

    Time frame: 28-day

  11. IMPROV domain - recruitment rate, protocol adherence, and vital status

    ≥0.75 patients randomized per site per month, Protocol adherence defined as \> 80% across participants, and ≥89% ascertainment of vital status and days alive and at home at day 90.

    Time frame: Throughout trial enrollment for recruitment rate and protocol adherence, and up to day 90 for vital status.

  12. WAVEFORM domain

    Duration of mechanical ventilation (MV)

    Time frame: considering death as a competing event

Secondary outcomes

  1. To assess adherence to our explicit mechanical ventilation protocols.

    Adherence to protocol defined as \>80% of patients having \<20% of monitored values determined to be major protocol deviations.

    Time frame: 48 hours

  2. To measure and understand the reasons for crossovers in each group

    Success for lack of crossovers defined as \<10% of crossovers between groups (when not allowed by protocol) in either direction.

    Time frame: 2 years

  3. Duration of mechanical ventilation during index ICU admission

    Measured in CORT-E2, IMV, IMV-ECLS and EXPAND-ECLS domains

    Time frame: Until ICU discharge, typically within 28 days

  4. Mortality at other endpoints

    Measured in CORT-E2, ESCAPE, FAST-3, IMV, IMV-ECLS, IMPROV and EXPAND-ECLS and WAVEFORM domains

    Time frame: ICU discharge, hospital discharge, day 30, 180 for CORT E2, IMV, IMV ECLS, and EXPAND ECLS.For ESCAPE:hospital mortality @ 60 days and 6 months.For FAST 3:all cause mortality @ 60 days post enrollment.For IMPROV:day 90.For WAVEFORM:day 28 after inclusion

  5. Vital status

    Measured in IMPROV domain

    Time frame: Day 90 and at 6 months

  6. Duration of ICU admission

    Measured in FAST-3, IMV, IMV-ECLS and EXPAND-ECLS and WAVEFORM domains

    Time frame: Until ICU discharge, typically within 28 days

  7. Hospital length of stay

    Measured in CORT-E2, FAST-3, IMV, IMV-ECLS and WAVEFORM domains

    Time frame: Until hospital discharge, assessed up to 4 weeks

  8. ICU and hospital free days

    Measured in FAST-3, IMPROV domains

    Time frame: For FAST-3: ICU discharge, hospital discharge, Day 28. For IMPROV: Day 90.

  9. Discharge disposition.

    Measured in IMV, IMV-ECLS, IMPROV domains. Location to which patient is discharged (e.g., home, weaning facility, etc.)

    Time frame: Until hospital discharge, assessed up to 4 weeks

  10. Days alive and at home to day 90

    Measured in IMV, IMV-ECLS and FLUDRO-1 and WAVEFORM domains

    Time frame: Day 90

  11. Need for ICU readmission prior to hospital discharge

    Measured in IMV, IMV-ECLS domains

    Time frame: Until hospital discharge, assessed up to 4 weeks

  12. Duration of NIV

    Measured in CORT-E2 domain

    Time frame: Until ICU discharge, typically within 28 days

  13. Duration of supplemental oxygen use

    Measured in CORT-E2 domain

    Time frame: Until ICU discharge, typically within 28 days

  14. Need for ECLS

    Measured in CORT-E2 domain

    Time frame: Until ICU discharge, typically within 28 days

  15. Duration of ECLS, only for patients who require ECLS

    Measured in CORT-E2, IMV-ECLS domains.

    Time frame: Until ICU discharge, typically within 28 days

  16. Ventilator-free days until day 30 for CORT-E2; until day 28 for FAST-3, FLUDRO-1, ULTIMATE and WAVEFORM( ordinal scale composed of survival to hospital discharge, days alive and free of ventilation where death in the hospital is assigned a score of -1).

    Measured in CORT-E2, FAST-3, FLUDRO-1, ULTIMATE and WAVEFORM domains.

    Time frame: Until day 30 for CORT-E2, and until day 28 for FAST-3, FLUDRO-1, ULTIMATE and WAVEFORM

  17. EQ-5-D at day 180

    Measured in CORT-E2, FAST-3, IMV, IMV-ECLS, IMPROV, WAVEFORM domains

    Time frame: For CORT-E2, FAST-3, IMV, and IMV-ECLS domains: Day 180; For IMPROV domain: Day 90 and Day 180.

  18. Montreal Cognitive Assessment (MoCA) At day 180

    Measured in FAST-3 domain

    Time frame: Day 180

  19. Complications from corticosteroids.

    Measured in CORT-E2 domain. Hypernatremia, hyperglycemia, delirium, clinically important GI bleeding, nosocomial infection, neuromuscular weakness. Measured in FLUDRO-1 domain: Hypernatremia, Hyperglycemia, Hypokalemia, Clinically important gastrointestinal bleeding, New nosocomial infection

    Time frame: Until hospital discharge, assessed up to 4 weeks

  20. Reintubation during index ICU admission

    Measured in IMV, IMV-ECLS domains

    Time frame: Until ICU discharge, typically within 28 days

  21. Number of reintubations up to tracheostomy during index hospitalization

    Measured in IMPROV domain

    Time frame: Until hospital discharge

  22. Tracheostomy during index ICU admission

    Measured in IMV, IMV-ECLS, IMPROV domains

    Time frame: Until ICU discharge, typically within 28 days

  23. Re-cannulation to ECLS during index ICU admission

    Measured in IMV-ECLS domain

    Time frame: Until ICU discharge, typically within 28 days

  24. Sequential Organ Failure Assessment (SOFA) score

    Measured in IMV, IMV-ECLS domains

    Time frame: Daily, for duration of intervention

  25. Respiratory mechanics and gas exchange - Driving pressure.

    Measured in IMV, IMV-ECLS domains.

    Time frame: Daily, for duration of intervention

  26. Respiratory mechanics and gas exchange - Pocc.

    Measured in IMV, IMV-ECLS domains.

    Time frame: Daily, for duration of intervention

  27. Respiratory mechanics and gas exchange - P0.1

    Measured in IMV, IMV-ECLS domains.

    Time frame: Daily, for duration of intervention

  28. Respiratory mechanics and gas exchange - plateau airway pressure

    Measured in IMV, IMV-ECLS domains.

    Time frame: Daily, for duration of intervention

  29. Respiratory mechanics and gas exchange - P/F ratio

    Measured in IMV, IMV-ECLS domains.

    Time frame: Daily, for duration of intervention

  30. Respiratory mechanics and gas exchange - ventilatory ratio

    Measured in IMV domain.

    Time frame: Daily, for duration of intervention

  31. Diaphragm thickness

    Measured in IMV domain

    Time frame: Daily, for duration of intervention

  32. Maximal diaphragm thickening fraction

    Measured in IMV domain

    Time frame: During first SBT

  33. Survival status at disconnection from mechanical ventilation (dead or alive)

    Measured in EXPAND-ECLS domain

    Time frame: Until day 28

  34. Organ failure-free days

    Measured in ESCAPE, FLUDRO-1 domains

    Time frame: Until day 28

  35. Serious adverse events (SAEs)

    Serious adverse events (SAEs) related to the intervention measured in FAST-3 domain

    Time frame: Throughout the trial

  36. Modified Lung Injury Score (mLIS)

    Measured in IMV-EIT intervention. Calculated daily up until study day 10 in patients who are alive and continue to have acute hypoxemic respiratory failure requiring invasive mechanical ventilation.

    Time frame: Until day 10

  37. Number of days from first SBT to disconnection from mechanical ventilation

    Measured in IMPROV domain - final date of extubation or the first day of continuous tracheostomy mask for at least 24 hours, provided ventilator support is not resumed during the index ICU admission.

    Time frame: Until ICU discharge

  38. Barotrauma during hospital admission

    Measured in IMPROV domain including pneumothorax, pneumomediastinum, subcutaneous emphysema

    Time frame: Until 45 days or hospital discharge

  39. Cardiac arrest during hospital admission

    Measured in IMPROV domain

    Time frame: Until 45 days or hospital discharge

  40. 30 second sit to stand test at ICU discharge and hospital discharge

    Measured in IMPROV domain

    Time frame: Until ICU discharge, typically within 28 days

  41. Modified Medical Research Council (mMRC) Dyspnea Scale

    Measured in IMPROV domain

    Time frame: At ICU discharge, Day 90, Day 180

  42. Physical function (Activity Measure for Post-Acute Care)

    Measured in IMPROV domain

    Time frame: At ICU discharge, Day 90, Day 180

  43. Days alive at day 180 after inclusion

    Measured in WAVEFORM domains

    Time frame: Day 180

  44. Incidence of abnormal PVIs in each ventilation strategy

    Measured in WAVEFORM domain

    Time frame: 7 days

  45. Sedation and NMBA use, type, simultaneous and cumulative dose

    Measured in WAVEFORM domain

    Time frame: 7 days, 28 days

  46. Vasopressor use, type, simultaneous and cumulative dose

    Measured in WAVEFORM domain

    Time frame: 7 days, 28 days

  47. PTSD symptoms (IES-R)

    Measured in WAVEFORM domain

    Time frame: Day 180

  48. Cognitive status (MoCA-BLIND)

    Measured in WAVEFORM domain

    Time frame: Day 180

07

Study locations

100 of 103 sites recruiting

Showing the first 100 of 103 sites across 10 countries. Choose a country and city above to see the rest.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.

Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 47 months is above that.

Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2021
First posted
Jul 1, 2022
StartActual
Apr 30, 2023
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
19 sites added, 5 sites removed — first site in Hong Kong. 3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • VA Ann Arbor Healthcare System · Ann Arbor, United StatesNot yet recruiting→Recruiting
  • London Health Sciences Centre - University Hospital · London, CanadaNot yet recruiting→Recruiting
  • Cité de la Santé Hospital · Laval, CanadaNot yet recruiting→Recruiting
Show 19 added (8 Italy, 4 Australia, 4 Spain, 1 United States, 1 Hong Kong, 1 New Zealand)
  • Texas Tech · El Paso, United States
  • St Vincent Hospital, Sydney · Darlinghurst, Australia
  • Peninsula University Hospital · Frankston, Australia
  • Westmead Hospital · Westmead, Australia
  • Queen Mary Hospital · Hong Kong, Hong Kong
  • Azienda Ospedaliero-Universitaria di Ferrara · Cona, Italy
  • Policlinico Riuniti Foggia · Foggia, Italy
  • Ospedale Maggiore, Fondazione IRCCS Ca Granda, Milano · Milan, Italy
  • ASST Grande Ospedale Metropolitano Niguarda · Milan, Italy
  • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone · Palermo, Italy
  • Policlinico Universitario Agostino Gemelli · Roma, Italy
  • Azienda Ospedaliero Universitaria - Sassari · Sassari, Italy
  • Ospedale Santa Chiara di Trento · Trento, Italy
  • Waikato Hospital · Hamilton, New Zealand
  • Hospital del Mar · Ciutat Vella, Spain
  • Vall d'Hebron University Hospital · Horta-Guinardó, Spain
  • Bellvitge University Hospital · L'Hospitalet de Llobregat, Spain
  • Hospital U Virgen de la Candelaria · Santa Cruz de Tenerife, Spain
  • The Prince Charles Hospital · Chermside, Australia
Show 5 removed
  • St Vincents Sydney · Darlinghurst, Australia
  • Universidad de La Sabana · Chía, Colombia
  • Ospedale Maggiore, Fondazione IRCCS Ca Granda, Milano · Milan, Italy
  • ASST Grande Ospedale Metropolitano Niguarda · Milan, Italy
  • Hospital Universitario de Getafe · Getafe, Spain
across 2 updates, Oct 6, 2026 – Oct 22, 2026
Site contacts
Changed at 18 sites. See the sites
Show 18 sites
  • University of Kentucky · Lexington, United StatesContact added p•••@uky.edu
  • Washington University · St Louis, United StatesContact p•••@wustl.edu · •••3461→k•••@wustl.edu · •••8762
  • Thomas Jefferson University Hospital · Philadelphia, United StatesContact •••5161→•••6591
  • Vanderbilt university medical center · Nashville, United StatesContact added t•••@vumc.org · •••5000Contact added (no phone or email listed)
  • Bendigo Health Victoria · Bendigo, AustraliaContact added c•••@bendigohealth.org.au
  • Nanaimo Regional General Hospital · Nanaimo, CanadaContact added D•••@islandhealth.ca · •••8000
  • Royal Jubilee Hospital · Victoria, CanadaContact added d•••@islandhealth.ca · •••8000Contact added (no phone or email listed)
  • Health Sciences Centre - Winnipeg · Winnipeg, CanadaContact added (no phone or email listed)
  • Ottawa Heart Research Institute · Ottawa, CanadaContact b•••@ottawaheart.ca · •••7381→b•••@ottawaheart.ca · •••7381
  • University Health Network · Toronto, CanadaContact added (no phone or email listed)
  • Azienda Socio-Sanitaria Territoriale Ovest Milanese · Legnano, ItalyContact added g•••@asst-ovestmi.it · •••9458
  • Auckland City Hospital · Grafton, New ZealandContact added T•••@adhb.govt.nz · •••7100
  • Middlemore Hospital · Auckland, New ZealandContact added T•••@cmdhb.org.nz · •••0000
  • Taranaki Base Hospital · New Plymouth, New ZealandContact added J•••@tdhb.org.nz · •••6139
  • Rotorua Hospital · Rotorua, New ZealandContact added U•••@lakesdhb.govt.nz · •••1199
  • King Abdulaziz Medical City- Riyadh · Riyadh, Saudi ArabiaContact added a•••@mngha.med.sa · •••1111
  • National University of Singapore · Singapore, SingaporeContact added m•••@nuhs.edu.sg · •••2222
  • Hospital Josep Trueta (Girona) · Girona, SpainContact added c•••@hotmail.com · •••0200
Oct 6, 2026
Show all 2 updates
  1. Oct 22, 2026
    1 site added
    Show site
    • The Prince Charles Hospital · Chermside, Australia
  2. Oct 6, 2026
    18 sites added, 5 sites removed — first site in Hong Kong. 3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • VA Ann Arbor Healthcare System · Ann Arbor, United StatesNot yet recruiting→Recruiting
    • London Health Sciences Centre - University Hospital · London, CanadaNot yet recruiting→Recruiting
    • Cité de la Santé Hospital · Laval, CanadaNot yet recruiting→Recruiting
    Show 18 added (8 Italy, 4 Spain, 3 Australia, 1 United States, 1 Hong Kong, 1 New Zealand)
    • Texas Tech · El Paso, United States
    • St Vincent Hospital, Sydney · Darlinghurst, Australia
    • Peninsula University Hospital · Frankston, Australia
    • Westmead Hospital · Westmead, Australia
    • Queen Mary Hospital · Hong Kong, Hong Kong
    • Azienda Ospedaliero-Universitaria di Ferrara · Cona, Italy
    • Policlinico Riuniti Foggia · Foggia, Italy
    • Ospedale Maggiore, Fondazione IRCCS Ca Granda, Milano · Milan, Italy
    • ASST Grande Ospedale Metropolitano Niguarda · Milan, Italy
    • Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone · Palermo, Italy
    • Policlinico Universitario Agostino Gemelli · Roma, Italy
    • Azienda Ospedaliero Universitaria - Sassari · Sassari, Italy
    • Ospedale Santa Chiara di Trento · Trento, Italy
    • Waikato Hospital · Hamilton, New Zealand
    • Hospital del Mar · Ciutat Vella, Spain
    • Vall d'Hebron University Hospital · Horta-Guinardó, Spain
    • Bellvitge University Hospital · L'Hospitalet de Llobregat, Spain
    • Hospital U Virgen de la Candelaria · Santa Cruz de Tenerife, Spain
    Show 5 removed
    • St Vincents Sydney · Darlinghurst, Australia
    • Universidad de La Sabana · Chía, Colombia
    • Ospedale Maggiore, Fondazione IRCCS Ca Granda, Milano · Milan, Italy
    • ASST Grande Ospedale Metropolitano Niguarda · Milan, Italy
    • Hospital Universitario de Getafe · Getafe, Spain
    Site contacts Changed at 18 sites. See the sites
    Show 18 sites
    • University of Kentucky · Lexington, United StatesContact added p•••@uky.edu
    • Washington University · St Louis, United StatesContact p•••@wustl.edu · •••3461→k•••@wustl.edu · •••8762
    • Thomas Jefferson University Hospital · Philadelphia, United StatesContact •••5161→•••6591
    • Vanderbilt university medical center · Nashville, United StatesContact added t•••@vumc.org · •••5000Contact added (no phone or email listed)
    • Bendigo Health Victoria · Bendigo, AustraliaContact added c•••@bendigohealth.org.au
    • Nanaimo Regional General Hospital · Nanaimo, CanadaContact added D•••@islandhealth.ca · •••8000
    • Royal Jubilee Hospital · Victoria, CanadaContact added d•••@islandhealth.ca · •••8000Contact added (no phone or email listed)
    • Health Sciences Centre - Winnipeg · Winnipeg, CanadaContact added (no phone or email listed)
    • Ottawa Heart Research Institute · Ottawa, CanadaContact b•••@ottawaheart.ca · •••7381→b•••@ottawaheart.ca · •••7381
    • University Health Network · Toronto, CanadaContact added (no phone or email listed)
    • Azienda Socio-Sanitaria Territoriale Ovest Milanese · Legnano, ItalyContact added g•••@asst-ovestmi.it · •••9458
    • Auckland City Hospital · Grafton, New ZealandContact added T•••@adhb.govt.nz · •••7100
    • Middlemore Hospital · Auckland, New ZealandContact added T•••@cmdhb.org.nz · •••0000
    • Taranaki Base Hospital · New Plymouth, New ZealandContact added J•••@tdhb.org.nz · •••6139
    • Rotorua Hospital · Rotorua, New ZealandContact added U•••@lakesdhb.govt.nz · •••1199
    • King Abdulaziz Medical City- Riyadh · Riyadh, Saudi ArabiaContact added a•••@mngha.med.sa · •••1111
    • National University of Singapore · Singapore, SingaporeContact added m•••@nuhs.edu.sg · •••2222
    • Hospital Josep Trueta (Girona) · Girona, SpainContact added c•••@hotmail.com · •••0200

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05440851
Responsible party
Sponsor
First posted
Jul 1, 2022
Start date
Apr 30, 2023
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Rongyu ( Cindy) Jin
Contact
rongyu.jin@uhn.ca
4163404800 ext. 7613
Cathy Chau
Contact
cathy.chau@uhn.ca
4167272260
Ewan Goligher, MD, PhD
study chair · University Health Network, Toronto
Eddy Fan, MD, PhD
study chair · University Health Network, Toronto
Niall Ferguson, MD, MSc
principal investigator · University Health Network, Toronto
Lorenzo Del Sorbo, MD
principal investigator · University Health Network, Toronto
Bram Rochwerg, MD, MSc
principal investigator · McMaster University
Bijan Teja, MD
principal investigator · Unity Health Toronto
John Muscedere, MD
principal investigator · Queens University
Laveena Munshi, MD
principal investigator · Mount Sinai Hospital, Canada
Dmitry Rozenberg, MD, PhD
principal investigator · University Health Network, Toronto
Anastasia Newman, PhD
principal investigator · McMaster University
Irene Telias, MD, PhD
principal investigator · University Health Network, Toronto
Andrea Castellvi Font, MD, PhD
principal investigator · Parc de Salut Mar, Spain
Laurent Brochard, MD
principal investigator · Unity Health Toronto

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion